How to appeal an Aetna prostate cancer denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna prostate cancer denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for prostate cancer
Cited policy: Aetna CPB on Talzenna (Talazoparib) + Xtandi (Enzalutamide) for HRR-mutated mCRPC
Adult mCRPC with HRR-gene alteration confirmed by FDA-approved test (FoundationOne CDx, BRACAnalysis CDx, or equivalent). HRR genes per TALAPRO-2: BRCA1/2, ATM, ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C. Castrate testosterone <50 ng/dL on ongoing ADT. ECOG 0-2. Talzenna 0.5 mg PO daily + Xtandi 160 mg PO daily continuous until progression or toxicity.
How Aetna denies prostate cancer — and how to counter it
Where Aetna pushes back: 1) PARPi only for BRCA1/2; 2) Try sequential ARSI then PARPi (cheaper); 3) HRR test result not from Aetna-preferred lab.
Counter-arguments that hold up: TALAPRO-2 Lancet 2023 + Nature Medicine 2024 (Fizazi HRR cohort) — talazoparib+enzalutamide rPFS 33.1 vs 19.5 mo (HR 0.45 HRR cohort, 0.63 all-comers). FDA-approved Jun 20, 2023 for HRR-mutated 1L mCRPC — label includes 11 HRR genes, NOT BRCA-only. Combination upfront superior to sequential — sequential ARSI then PARPi delays effective therapy. NCCN v1.2025 + AUA Advanced 2023 endorse upfront combination. Any FDA-approved HRR companion-diagnostic test (CDx) is acceptable per FDA labeling.
What Aetna typically denies for prostate cancer
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Pluvicto (177Lu-PSMA-617)
- Xofigo (radium-223)
- Xtandi (enzalutamide)
- Erleada (apalutamide)
- Nubeqa (darolutamide)
- Zytiga (abiraterone)
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna prostate cancer denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for prostate cancer?
For prostate cancer, Aetna most often denies on: 1) PARPi only for BRCA1/2; 2) Try sequential ARSI then PARPi (cheaper); 3) HRR test result not from Aetna-preferred lab. The strongest counters: TALAPRO-2 Lancet 2023 + Nature Medicine 2024 (Fizazi HRR cohort) — talazoparib+enzalutamide rPFS 33.1 vs 19.5 mo (HR 0.45 HRR cohort, 0.63 all-comers). FDA-approved Jun 20, 2023 for HRR-mutated 1L mCRPC — label includes 11 HRR genes, NOT BRCA-only. Combination upfront superior to sequential — sequential ARSI then PARPi delays effective therapy. NCCN v1.2025 + AUA Advanced 2023 endorse upfront combination. Any FDA-approved HRR companion-diagnostic test (CDx) is acceptable per FDA labeling.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Prostate cancer appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com